Modalis Therapeutics Corporation

4883 株式会社モダリス

Drug Manufacturers - Specialty & Generic · Growth

PRICE: ¥34 · MKT CAP: ¥2.9B · P/E: — · P/B: 1.07x · DIV YIELD: 0.0%

PRICE — 5Y

Characteristics & Business Summary

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing...

Income Statement Highlights (¥ Million, except EPS/DPS in ¥)

Fiscal Period	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Net Sales	342	1	40	—	—	—
Operating Profit	-398	-1,239	-2,063	-2,371	-1,338	-2,212
Ordinary Profit	-440	-1,231	-1,996	-2,352	-1,303	-2,149
Net Profit	-448	-739	-2,703	-2,392	-1,318	-2,153
EPS	¥-16	¥-26	¥-92	¥-72	¥-19	¥-25
DPS	¥0	¥0	¥0	¥0	¥0	¥0

Balance Sheet & Valuation Highlights

Total Assets ¥3B

Net Assets (Equity) ¥3B

Equity Ratio 93.0%

ROE (Return on Equity) -78.5%

Cash & Equivalents ¥3B

Interest-Bearing Debt ¥0B

Capital Expenditure (CapEx) ¥0B

Depreciation & Amort. —

Major Shareholders

1. 株式会社LSIM 3.3%
2. Rakuten Securities, Inc. 3.1%
3. SBI Securities Co., Ltd. 2.9%
4. BNP PARIBAS LONDON BRANCH FOR PRIME BROKERAGE CLEARANCE ACC FOR THIRD PARTY （常任代理人香港上海銀行東京支店） 2.7%
5. 近藤誠聡 2.1%
6. 濡木理 1.8%
7. State Street Bank and Trust Company 1.1%
8. マネックス証券株式会社 0.8%
9. Matsui Securities Co., Ltd. 0.8%
10. 株式会社証券ジャパン 0.7%

Activist Activity

Haruhiko Morita (LSIM Inc.) 5.39%

2026-05-27 · decrease

Haruhiko Morita 5.63%

2026-05-01 · change

Evo Fund 4.0%

2026-05-01 · change

Evo Fund 4.99%

2026-04-24 · change

Evo Fund 5.92%

2026-04-15 · change

Historical Per-Share Data & Valuation Ratios

Per Share Metric	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenues per share	¥12	¥0	¥1	—	—	—
FCF/Share	¥-14	¥-30	¥-71	¥-69	¥-21	¥-24
EPS	¥-16	¥-26	¥-92	¥-72	¥-19	¥-25
DPS	¥0	¥0	¥0	¥0	¥0	¥0
Capital Spending per share	¥1	¥4	¥7	¥1	¥0	¥0
Book Value per share	¥218	¥191	¥99	¥40	¥51	¥32
Common Shares Outstanding	29M	29M	29M	33M	69M	87M

Financial Aggregates & Margins

Financial Aggregate	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenues (Net Sales)	¥0B	¥0B	¥0B	—	—	—
Operating Margin (%)	-116.5%	-112676.7%	-5094.3%	—	—	—
Net Profit (owners)	¥-0B	¥-1B	¥-3B	¥-2B	¥-1B	¥-2B
Net Profit Margin (%)	-131.1%	-67177.8%	-6673.4%	—	—	—
Working Capital	¥5B	¥5B	¥3B	¥1B	¥3B	¥3B
Total Debt (Interest-bearing)	¥0B	¥0B	¥0B	¥0B	¥0B	¥0B
Net Worth (Common Equity)	¥6B	¥6B	¥3B	¥1B	¥4B	¥3B
Return on Total Assets (ROA)	-7.1%	-12.2%	-86.4%	-118.1%	-35.7%	-72.6%
Return on Common Equity (ROE)	-7.2%	-13.3%	-93.0%	-177.6%	-37.5%	-78.5%

Business Summary & Analysis

Capital Strategy Targets

No active capital policy disclosure records found.